Few fields have moved faster in longevity science over the past decade than the study of cellular senescence. And few have generated more therapeutic optimism.
What was once little more than a curiosity of cellular biology has become a leading framework for understanding the aging process. It has also become a legitimate (and concrete) target for intervention.
What Is Cellular Senescence?
Senescence occurs when a cell stops dividing…but does not die. Unlike quiescent cells—which stop dividing temporarily—senescent cells are arrested for good. They cannot re-enter the cycle of cellular division, even when conditions become favorable.
Senescence is not inherently pathological. It actually evolved as a protective mechanism. When a cell is damaged—from DNA strand breaks, oxidative stress, oncogene activation, or telomere shortening—senescence prevents that damaged cell from proliferating (and potentially becoming cancerous).
Problems arise when senescent cells accumulate. Earlier in life, the immune system efficiently clears senescent cells from the body through a process called immune surveillance. But with age, this process becomes less effective. The result is senescent cells that build up within tissues throughout the body. By the time a person reaches their 60s, senescent cells can make up anywhere from 5 to 15% of the cells in some tissues—a seemingly small fraction that has outsized consequences.
The Senescence-Associated Secretory Phenotype (SASP)
What makes accumulated senescent cells harmful is what they secrete. Senescent cells release a complex mix of pro-inflammatory cytokines, chemokines, growth factors, proteases, and extracellular matrix components collectively called the “senescence-associated secretory phenotype” (or SASP).
SASP was originally adaptive. Its pro-inflammatory signals recruit immune cells that clear out senescent cells and help to repair tissue. But when senescent cells persist—particularly in large numbers—chronic SASP output creates a state of low-grade inflammation (sometimes called inflammaging). This sustained inflammatory environment damages surrounding cells, disrupts tissue architecture, impairs stem cell function, and drives many hallmarks of the aging process.
Senescence Is Not Uniform
Not all senescent cells are alike. Emerging research indicates that senescent cell populations vary widely depending upon cell type, the trigger that induced senescence, and how long the cell has been senescent.
This diversity of cell type—sometimes called the “senotype”—has significant implications when it comes to therapeutics, since no single target will work across all senescent cell populations. In other words, different tissues accumulate different types of senescent cells, with different surface markers and different SASP compositions.
Enter Senotherapeutics (A Framework for Intervention)
The term “senotherapeutics” refers broadly to any therapy that targets senescent cells. The field is divided into three main strategic approaches:
- Senolytics that kill senescent cells.
- Senomorphics (also called senostatics) that modulate senescent cell behavior without eliminating them.
- Cellular Reprogramming, which aims to restore youthful gene expression within senescent cells.
Eliminating Senescent Cells (Senolytics)
Senolytics exploit senescent cells’ unusual dependence on pro-survival pathways. Because senescent cells are damaged and continually producing toxic SASP, they require upregulation of survival pathways. By targeting these survival pathways, senolytics selectively target senescent cells, while leaving healthy cells intact.
Dasatinib and Quercetin (D+Q)
The most extensively studied senolytic combination is dasatinib (a tyrosine kinase inhibitor approved for the treatment of leukemia), combined with quercetin (a plant-derived flavonoid).
These two compounds are complementary in that dasatinib primarily targets senescent fat cell progenitors and epithelial cells, while quercetin works more broadly across multiple cell types. Together, they inhibit multiple pro-survival pathways that senescent cells rely upon.
Clinically, D+Q is administered in intermittent “hit-and-run” pulses (two to three consecutive days per cycle, repeated monthly) rather than continuous dosing. This pulsing approach is preferable because once cleared, senescent cells take time to re-accumulate—making sustained daily dosing unnecessary.
Clinical trials with D+Q have explored several conditions. In a small pilot trial published in 2019, the combination reduced senescent cell burden in adipose tissue from patients with idiopathic pulmonary fibrosis (IPF)—a devastating disease with essentially no other treatment options at the time—and was associated with improved physical function. A 2025 trial tested D+Q in osteoarthritis, demonstrating that the combination selectively eliminated senescent chondrocytes and enhanced the production of anabolic growth factors, suggesting disease-modifying potential. A pilot trial in patients with mild cognitive impairment has produced preliminary results that are being analyzed, and a trial targeting age-related cognitive decline in older adults with mental health conditions is actively recruiting.
Fisetin
Fisetin is a naturally occurring flavonoid found in strawberries, apples, and other plants. Preclinical studies have shown that fisetin extended lifespan in aged mice and reduced senescent cell markers more effectively than many other plant polyphenols tested.
Fisetin’s mechanism involves inhibition of specific pro-survival signaling pathways that senescent cells rely upon. It’s also a potent antioxidant and anti-inflammatory. Like quercetin, fisetin is available as a supplement, and intermittent high-dose protocols are being explored clinically. While fisetin appears to have a favorable safety profile, its primary challenge (as with many polyphenols) is bioavailability, which has driven interest in optimized formulations.
Silencing the SASP (Senomorphics)
Rather than eliminating senescent cells outright, senomorphics suppress harmful SASP secretion (while leaving the cells alive). This approach may be preferable when senescent cells still perform beneficial functions (such as wound healing), where complete elimination is difficult, or where a patient cannot tolerate the potential adverse effects of senolytic agents.
Rapamycin
Rapamycin is an FDA-approved immunosuppressant that inhibits the activity of mTOR (otherwise known as the “mechanistic target of rapamycin”)—an enzyme that regulates cell growth.
Rapamycin is the most studied and arguably the most well-supported pharmacological longevity intervention within preclinical models. Impressively, it has been shown to extend median and maximum lifespans within mice when initiated at any age, including late in life.
Its senomorphic mechanism centers on mTOR’s role in SASP regulation. By inhibiting mTORC1 specifically (a protein complex that acts as a cell growth switch), rapamycin suppresses downstream SASP amplification.
Rapamycin also promotes autophagy—a sort of cellular “self-cleaning”—which may help to clear out damaged proteins and organelles that would otherwise drive senescent signaling.
Clinically, rapamycin has been shown to improve immune function in elderly adults and is being tested in multiple human longevity trials. Weekly (rather than daily) dosing aims to preserve rapamycin’s benefits, while reducing its risks.
Metformin
Metformin, the world’s most widely prescribed diabetes drug, activates AMPK (AMP-activated protein kinase), which reduces pro-inflammatory cytokine secretion from senescent cells. Metformin also has indirect effects on SASP by lowering mTOR signaling and reducing oxidative stress.
The large-scale TAME (Targeting Aging with Metformin) trial—a landmark clinical trial testing whether metformin can delay age-associated illness—is currently ongoing. TAME is tracking composite endpoints including cardiovascular disease, cancer, dementia, and mortality in adults aged 65–79. The trial represents a historic milestone in that it’s the first clinical trial designed with delaying the aging process as its explicit goal. Results are anticipated in the late 2020s.
JAK Inhibitors (Ruxolitinib and Baricitinib)
JAK (Janus kinase) inhibitors suppress a specific signaling pathway that is a significant downstream mediator of SASP cytokines. By blocking JAK, these drugs reduce the production and effect of inflammatory cytokines and interferons.
Ruxolitinib, approved for myelofibrosis and certain other conditions, has shown senomorphic activity in preclinical models. In a pilot human study, topical ruxolitinib reversed some indicators of skin aging in older adults—reducing features of skin senescence and improving structural integrity. Baricitinib, approved for rheumatoid arthritis and COVID-19, has been similarly explored within the context of SASP suppression.
JAK inhibitors are attractive senomorphics because they have established safety profiles and are already approved in humans.
Currently Available Senotherapeutics
To be clear…no drug has received regulatory approval specifically as a senolytic or senomorphic for anti-aging indications. The FDA does not currently recognize “aging” as a disease for which drugs can be approved, though this may change with the TAME trial precedent.
Having said that, several compounds with senotherapeutic activity are clinically available either because they have been approved for other purposes or because they are classified as supplements:
Dasatinib is FDA-approved for chronic myelogenous leukemia and acute lymphoblastic leukemia. It is a prescription drug.
Quercetin and fisetin are widely available as over-the-counter dietary supplements. High-dose intermittent protocols are being explored in clinical settings.
Rapamycin is FDA-approved as an immunosuppressant for organ transplant and certain other rare conditions. It is increasingly being prescribed off-label for anti-aging purposes in low-dose intermittent regimens.
Metformin is FDA-approved for type 2 diabetes and is prescribed off-label for anti-aging purposes, pending TAME trial results.
JAK inhibitors (ruxolitinib and baricitinib) are FDA-approved for various inflammatory and oncological indications. They are prescription drugs.
Therapies in Development
Next-Generation Senolytics
Several companies are advancing proprietary senolytic compounds through clinical trials. This is an area to watch.
Gene Therapy and Precision Senolysis
Non-viral gene therapies are in development for body-wide delivery. The most promising approach deliveries a “suicide gene” to senescent cells that would not affect normal cells. Theoretically, this approach offers high selectivity and, importantly, can be dosed repeatedly. Human trials are on the horizon.
Immune-Based Senolysis
One of the most exciting emerging approaches is harnessing the immune system to clear out senescent cells.
Senescent cells express a distinct set of surface antigens not found on healthy cells—dubbed “seno-antigens”. Approaches under development include:
- CAR-T cells—cells that are engineered to recognize and kill senescent cells that are expressing specific surface markers.
- Senolytic vaccines—this approach would train the immune system to recognize and destroy senescent cells.
- Bispecific antibodies—antibodies that are engineered to recruit immune cells that destroy senescent cells.
Partial Cellular Reprogramming
This is a conceptually distinct but related approach that involves resetting the epigenetic age of senescent cells. Called partial reprogramming, this technique has reversed senescence markers and improved function in muscle, retinal, and neuronal cells in preclinical models. Human trials remain years away, but the field is moving quickly.
Senolytic Antibody-Drug Conjugates
Borrowing from oncology, researchers are developing antibody-drug conjugates (ADCs) that deliver senolytic payloads directly to senescent cells by targeting surface antigens. This approach could dramatically increase potency and selectivity while minimizing systemic exposure.
Challenges and Open Questions
Several important challenges temper the current optimism.
First, most human clinical data is from small trials. The field lacks large, randomized, placebo-controlled studies demonstrating that clearing senescent cells prevents disease or extends healthspan in humans.
Second, senescent cells are not uniform. A single senolytic may work well against one population of cells and miss another entirely (especially across different tissue types).
Third, the right dose, timing, and frequency of senolytic administration remain poorly established for humans.
Fourth, some senescent cells perform beneficial functions relative to tissue repair, and indiscriminate clearance could impair wound healing.
Fifth, aging is multifactorial. Even perfect senolytic clearance addresses only one of many processes underlying biological aging.
Nonetheless, the field has crossed some important thresholds. There are now specific molecular mechanisms, measurable biomarkers, targeted therapeutics, and early human clinical data. Whether senolytics and senomorphics can deliver on their preclinical promise will be a defining question in years to come.
Conclusion
Cellular senescence sits at the intersection of cancer biology, inflammation, and aging—a fundamental cellular mechanism that is protective in the short term…but damaging when chronic.
In less than a decade, the idea that selectively eliminating or silencing these cells could reverse aspects of the aging process has evolved from being a speculative hypothesis, to being a legitimate clinical endeavor.
The decade ahead will determine whether senotherapeutics becomes a pillar of longevity medicine…or remains a promising but elusive target. Either way, the science has fundamentally altered how we understand aging and has started a real-world conversation about potential interventions.
At Renew Youth, we lead the conversation on age management. We can tell you about treatments that are available now…as well as treatments that are on the horizon. Would you like to learn more? Call us at (800) 859-7511 or use our easy contact form to schedule your complimentary 30-minute consultation.